# Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

> **NCT05983783** · PHASE3 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Prostate Cancer
- Hormone Sensitive Prostate Cancer
- Chemotherapy Effect

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Rezvilutamide

## Key facts

- **NCT ID:** NCT05983783
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983783, "Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05983783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*